Kaitai Capital is a Hangzhou-based private equity and venture capital firm founded in 2009 that specializes in innovative and industrial. See contact routes.
Kaitai Capital is a Hangzhou-based private equity and venture capital firm founded in 2009 that specializes in innovative and industrial investments alongside wealth management services. The firm’s investment thesis targets biopharma, healthcare services, agriculture technology, consumer business, and digital technology across seed to Series C stages, with a primary focus on the Chinese market. While specific check sizes and lead/follow behavior are not publicly disclosed, the firm manages approximately 50 billion yuan ($7.5 billion) in assets under management and demonstrates flexibility in supporting companies at different growth phases. Notable portfolio companies include OncoC4, Rgenta Therapeutics, Teon Therapeutics, and ABM Therapeutics, reflecting its deep concentration in biomedicine and precision medicine. Partner and CEO Yonghong Xu has publicly emphasized a strategic shift to enhance and concentrate investments in healthcare, particularly in biomedicine, oncology, and gene therapies. The firm distinguishes itself by focusing on next-generation reagents, small molecular targeted drugs, and gene and cell therapies within its healthcare sector.
Details on this firm come from filing and round data held in the StartupFundraising directory, refreshed on ingest. Founders use profiles like this one to qualify fit and to shortlist comparable investors.
Investors like Kaitai Capital · Full investor directory · Investor access · Company funding database